

**In the matter of the Canadian Anti-Doping Program;**

**And the matter of an anti-doping rule violation by Munkhjin Batdorj asserted by the Canadian Centre for Ethics in Sport;**

**File outcome summary**

**Summary**

1. The CCES conducted an In-Competition Sample collection session on May 21, 2023 in Montréal, QC.
2. Munkhjin Batdorj (“the Athlete”) was selected for Doping Control. The Athlete’s Sample code was 7086897. The Sample provided by the Athlete returned an Adverse Analytical Finding (AAF) for Trenbolone metabolite (epitrenbolone) (“Trenbolone”), a non-specified Prohibited Substance.
3. Following receipt of the CCES’s Notice of Charge asserting an anti-doping rule violation (ADRV) for the presence and Use of Trenbolone, the Athlete waived his right to a hearing, admitted the violation and accepted a two (2) year period of Ineligibility and all other applicable Consequences by signing an Agreement on Consequences, all of which is reflected below.

**Jurisdiction**

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and implements the Canadian Anti-Doping Program (CADP), including providing anti-doping services to national Sport Organizations and their members.
5. As Canada’s National Anti-Doping Organization, the CCES is compliant with the World Anti-Doping Code (“the Code”) and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The CADP was issued for adoption by Canadian Sport Organizations on October 26, 2020, to be operational on January 1, 2021. Judo Canada adopted the CADP on December 7, 2020; therefore, the CADP applies to all members, registrants, license-holders, or Participants of Judo Canada. The Athlete is a member of and participates in the activities of Judo Canada; therefore, as a Participant in Judo Canada activities, the Athlete is subject to the CADP.

**Doping Control**

7. On May 21, 2023, the CCES conducted an In-Competition Sample collection session in Montreal, QC. Testing was conducted as part of the CCES’s domestic test distribution plan, all pursuant to the CADP.
8. The Athlete was notified that he had been selected for Doping Control and, together with the Doping Control Officer (DCO) from the CCES, completed the Sample collection process. The

Athlete's Sample code was 7086897.

9. On May 21, 2023, the Athlete's urine Sample was received by the INRS Centre Armand-Frappier Santé Biotechnologie ("the INRS"), a World Anti-Doping Agency (WADA) accredited laboratory in Laval, QC.

### **Results Management**

10. The AAF was reported by the INRS on June 2, 2023. The Certificate of Analysis indicated the presence of Trenbolone, which had an estimated concentration of 1ng/mL.
11. Trenbolone is classified as a non-Specified Substance on WADA's 2023 Prohibited List
12. The CCES commenced an initial review into the Athlete's AAF and issued a notification of a potential ADRV on June 14, 2023.
13. On June 26, 2023, the Athlete accepted a voluntary Provisional Suspension
14. On September 21, 2023, the CCES formally issued a Notice of Charge asserting an ADRV against the Athlete for the presence and Use of a Prohibited Substance
15. In accordance with CADP Rule 10.2.2, the sanction for an ADRV involving the presence and Use of a non-specified Substance is a four (4) year period of Ineligibility. The CCES asserted a four (4) year period of Ineligibility in its Notice of Charge of September 21, 2023.
16. On March 25, 2024, after assessing all the information provided by the Athlete, the CCES agreed to a two (2) year period of ineligibility based on the determination that the Athlete's ADRV was not intentional. On April 2, 2024, the Athlete confirmed he accepted a two (2) year period of Ineligibility.

### **Confirmation of Violation and Sanction**

17. On May 15, 2024, and in accordance with CADP Rule 8.4.1, the Athlete signed an Agreement on Consequences and waived his right to a hearing, thereby admitting the ADRV and accepting both the asserted violation and a two-year period of Ineligibility, in addition to all other applicable Consequences. Accordingly, effective May 15, 2024, an ADRV was confirmed against the Athlete for the presence and Use of Trenbolone pursuant to CADP Rule 10.2.3. The sanction for this ADRV is a two (2) year period of Ineligibility, which commenced on June 26, 2023 (the date the Athlete accepted a Provisional Suspension) and will conclude on June 25, 2025.
18. Further, in accordance with CADP Rules 9, 10.1 and 10.10, any competitive results obtained by the Athlete during the May 21, 2023 event, and from any subsequent Event up to the date that the Athlete accepted a voluntary Provisional Suspension (June 26, 2023), must be Disqualified.

19. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 8<sup>th</sup> day of August 2024.



---

Kevin Bean  
Executive Director, Sport Integrity  
CCES